Vitality Watch

Dossier pubmed observational 11-sep-2026
Human cohort, case-control, or epidemiological association

Divergent amino acid profiles in sarcopenic obesity versus non-obese sarcopenia: A prospective cohort study in community-dwelling older adults.

Key claim: In community-dwelling older adults, higher serum BCAAs and aromatic amino acids are inversely associated with non-obese sarcopenia but positively associated with sarcopenic obesity, arguing against uniform amino-acid supplementation.

Abstract

BACKGROUND: The roles of branched-chain amino acids (BCAAs) and aromatic amino acids (AAAs) in sarcopenia remain conflicting, largely due to the overlooked impact of obesity. Whether these AAs differentially associate with sarcopenia without obesity (sarcopenia-only) versus sarcopenic obesity (SO) is unknown. This study evaluated their cross-sectional and prospective associations and explored dietary determinants. METHODS: This prospective study included 2994 community-dwelling Chinese older adults. Serum BCAAs and AAAs were quantified at baseline. Multivariable multinomial logistic regression examined cross-sectional (baseline and 14-year) and exploratory prospective (4-year and 14-year) associations with incident sarcopenia-only and SO. Dietary intake was assessed using a validated food frequency questionnaire. RESULTS: Cross-sectionally, each 1‑SD increment in BCAAs and AAAs was associated with lower sarcopenia-only risk (all ORs < 1, P < 0.05), whereas higher valine (OR = 1.195, P = 0.032) and isoleucine (OR = 1.221, P = 0.016) were associated with increased SO risk. The 14‑year cross‑sectional analysis confirmed the positive association between BCAAs and SO (ORs: 1.604-1.668, all P < 0.01). Prospectively over 4 years, higher baseline BCAAs and tyrosine were associated with lower sarcopenia-only risk (all ORs < 1, P < 0.05). Conversely, higher baseline isoleucine and phenylalanine emerged as short-term risk factors for incident SO (ORs: 1.233-1.331, P < 0.05). Exploratory 14‑year analyses showed directionally consistent associations, with valine inversely associated with sarcopenia‑only (OR = 0.628, P = 0.024) and BCAAs positively associated with SO (ORs: 1.555-1.693, P < 0.01). Dietary patterns differed, with sarcopenia-only showing lower fiber/vegetable intake but higher red/processed meat consumption (all P < 0.05), whereas SO showed elevated hs‑CRP (P < 0.05) and tended to have a higher dietary inflammatory index. CONCLUSIONS: In community‑dwelling older adults, serum BCAAs and AAAs were inversely associated with sarcopenia-only but positively associated with SO. The consistency of these associations across time points supports their utility as potential concurrent metabolic markers for phenotype differentiation. These distinct profiles, alongside dietary correlates, caution against uniform AA supplementation and suggest phenotype-specific nutritional strategies in older adults.

Why this matters

Sarcopenia guidance in aging tends to default to ‘more protein, more amino acids,’ but this cohort splits older adults into non-obese sarcopenia (where higher BCAAs and aromatic amino acids track with lower risk) versus sarcopenic obesity (where the same amino acids track with higher risk). It reframes the protein-in-aging question as phenotype-dependent rather than a single dose-response curve, and connects the protein-intake and obesity-aging pages through a shared metabolic signature.

Source

Link

Briefing card

Divergent amino acid profiles in sarcopenic obesity versus non-obese sarcopenia: A prospective cohort study in community-dwelling older adults.
Stage: observational · pubmed · 11-sep-2026

If you're an older adult considering BCAA or amino-acid supplements for muscle loss, this cohort suggests the risk-benefit likely differs depending on whether you also carry excess adiposity.

In community-dwelling older adults, higher serum BCAAs and aromatic amino acids are inversely associated with non-obese sarcopenia but positively associated with sarcopenic obesity, arguing against uniform amino-acid supplementation.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1016/j.jnha.2026.100985

build build 880 · 2bcef25 · 2026-11-18